Most Active Stocks After Hours on October 6, 2025: SOFI, BMEA, PPH, NVDA, CSCO, CMCSA
NASDAQ 100 After Hours Performance: The NASDAQ 100 is down 1.4 points to 24,977.16, with a total after-hours trading volume of 125,725,242 shares.
Most Active Stocks: SoFi Technologies (SOFI) is up 0.24 at $26.60, Biomea Fusion (BMEA) is up 0.6287 at $3.30, and VanEck Pharmaceutical ETF (PPH) is up 0.3956 at $94.12, while Cisco Systems (CSCO) and NVIDIA (NVDA) remain unchanged.
Trade with 70% Backtested Accuracy
Analyst Views on BMEA
About BMEA
About the author
Biomea Fusion to Present at 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
- Conference Presentation: Biomea Fusion's Interim CEO Dr. Mick Hitchcock will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, from 5:15 PM to 5:55 PM Pacific Time, aiming to enhance the company's visibility among investors and showcase its R&D progress.
- One-on-One Meeting Opportunities: Throughout the conference, Biomea's management team will host one-on-one meetings, providing a platform for in-depth discussions with potential investors, thereby fostering stronger relationships and attracting more attention to the company.
- Product Development Focus: Biomea Fusion is advancing oral small molecule therapies icovamenib and BMF-650 for diabetes and obesity, targeting metabolic disorders that affect nearly half of Americans and one-fifth of the global population, highlighting its strategic positioning in the biopharmaceutical sector.
- Company Mission and Vision: Biomea's mission is to deliver transformative treatments for patients living with diabetes, obesity, and related conditions, aiming to improve patient health through innovative drug development, which underscores the company's significant role in addressing global health challenges.
Biomea Fusion Unveils Clinical Results of Icovamenib, Advancing Diabetes Treatment
- Clinical Results Showcase: Biomea Fusion presented clinical findings on icovamenib at WCIRDC 2025, highlighting its potential efficacy in diabetes patients, which could position it as a new treatment option in diabetes care.
- Expert Interview Highlights: Renowned expert Dr. Ralph DeFronzo discussed the mechanism of icovamenib and its prospects in combination with GLP-1 therapies, indicating that the drug may improve insulin secretion and glycemic control.
- Market Demand Analysis: With approximately 38 million people in the U.S. suffering from diabetes and the significant economic burden of diabetes treatment, the development of icovamenib aims to address this substantial medical need, particularly for patients with severe insulin-deficient diabetes.
- Future Development Strategy: Biomea Fusion emphasizes the swift advancement of icovamenib's clinical studies to meet the urgent need for restoring insulin secretion function in diabetes patients, demonstrating the company's strategic commitment to the diabetes treatment landscape.
Biomea Fusion Unveils Clinical Results of Icovamenib, Advancing Diabetes Treatment
- Clinical Results Announcement: Biomea Fusion presented clinical findings on icovamenib at WCIRDC 2025, highlighting its potential efficacy in diabetes patients, which could position it as a new treatment option to meet the urgent market demand for innovative therapies.
- Key Opinion Leader Interview: Renowned expert Dr. Ralph DeFronzo discussed the mechanistic rationale for menin inhibition and the prospects of combining icovamenib with GLP-1 therapies, showcasing the drug's potential to improve glycemic control and insulin secretion, which may transform the diabetes treatment landscape.
- Market Demand Analysis: With approximately 38 million people in the U.S. living with diabetes and one in four healthcare dollars spent on diabetes care, the market potential for icovamenib is substantial, addressing a significant unmet medical need.
- Future Development Direction: Biomea Fusion emphasized the acceleration of icovamenib's clinical studies to address the high risks and rapid progression of severe insulin-deficient diabetes patients, demonstrating the company's strategic commitment to advancing diabetes care.
Biomea Fusion Highlights Long-lasting Advantages of Menin Inhibitor for Type 2 Diabetes
Study Presentation: Biomea Fusion Inc. presented new data from its COVALENT-111 study on Icovamenib for type-2 diabetes at the WCIRDC in Los Angeles, highlighting its potential to improve glycemic control in patients with inadequate management.
Mechanism and Results: Icovamenib, an investigational Menin inhibitor, showed durable improvements in glycemic levels and C-peptide after treatment, with better outcomes linked to higher drug exposure, and was well tolerated with no serious adverse events reported.
Future Trials: The company plans to initiate Phase IIb and Phase II trials (COVALENT-211 and COVALENT-212) in severe insulin-deficient type-2 diabetes and in combination with GLP-1 therapy, respectively, expected to start in Q4 2025.
Stock Performance: Biomea Fusion's stock is currently trading at $1.36, reflecting a 15.11% increase, with a 12-month trading range between $0.87 and $6.57.
Biomea Fusion Presents COVALENT-111 Study Results, New Breakthrough in Diabetes Treatment
- Study Results Presentation: Biomea Fusion presented COVALENT-111 study results at the WCIRDC in Los Angeles, demonstrating that icovamenib achieved durable improvements in HbA1c and C-peptide in patients with severe insulin-deficient type 2 diabetes, indicating its potential in diabetes treatment.
- Significant Clinical Effects: The study results showed a notable correlation between icovamenib use and HbA1c reduction, with treatment effects persisting nine months post last dose, suggesting its long-term efficacy.
- Good Safety Profile: In clinical trials, icovamenib was well-tolerated with no discontinuations due to adverse events, indicating a high safety profile that could enhance market acceptance among patients.
- Future Development Potential: As the first non-chronic therapy for type 2 diabetes, icovamenib could represent a significant innovation in diabetes treatment if it successfully completes ongoing clinical studies, addressing the growing global demand for diabetes management solutions.
Biotech Stocks Rise After Hours: Clene Jumps Ahead of ALS Update; Werewolf, Biomea, and Dyne Also Gain
Clene Inc. Gains: Clene Inc. shares rose 8.53% in after-hours trading after announcing an upcoming investor call regarding its CNM-Au8 program for ALS, despite a regular session decline.
Werewolf Therapeutics Update: Werewolf Therapeutics saw a 6.12% increase after hours, likely influenced by investor reactions to its recent presentation at a cancer immunotherapy conference, despite no new news.
Biomea Fusion Presentation: Biomea Fusion's stock climbed 7.31% after hours following its announcement of an upcoming presentation on icovamenib data at a major diabetes and cardiovascular disease congress.
General Market Trends: Other biotech companies like Denali Therapeutics, TScan Therapeutics, and Nyxoah also experienced after-hours gains, reflecting ongoing investor interest and positioning ahead of regulatory milestones and presentations.
Biomea Fusion to Present at 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
- Conference Presentation: Biomea Fusion's Interim CEO Dr. Mick Hitchcock will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, from 5:15 PM to 5:55 PM Pacific Time, aiming to enhance the company's visibility among investors and showcase its R&D progress.
- One-on-One Meeting Opportunities: Throughout the conference, Biomea's management team will host one-on-one meetings, providing a platform for in-depth discussions with potential investors, thereby fostering stronger relationships and attracting more attention to the company.
- Product Development Focus: Biomea Fusion is advancing oral small molecule therapies icovamenib and BMF-650 for diabetes and obesity, targeting metabolic disorders that affect nearly half of Americans and one-fifth of the global population, highlighting its strategic positioning in the biopharmaceutical sector.
- Company Mission and Vision: Biomea's mission is to deliver transformative treatments for patients living with diabetes, obesity, and related conditions, aiming to improve patient health through innovative drug development, which underscores the company's significant role in addressing global health challenges.
Biomea Fusion Unveils Clinical Results of Icovamenib, Advancing Diabetes Treatment
- Clinical Results Showcase: Biomea Fusion presented clinical findings on icovamenib at WCIRDC 2025, highlighting its potential efficacy in diabetes patients, which could position it as a new treatment option in diabetes care.
- Expert Interview Highlights: Renowned expert Dr. Ralph DeFronzo discussed the mechanism of icovamenib and its prospects in combination with GLP-1 therapies, indicating that the drug may improve insulin secretion and glycemic control.
- Market Demand Analysis: With approximately 38 million people in the U.S. suffering from diabetes and the significant economic burden of diabetes treatment, the development of icovamenib aims to address this substantial medical need, particularly for patients with severe insulin-deficient diabetes.
- Future Development Strategy: Biomea Fusion emphasizes the swift advancement of icovamenib's clinical studies to meet the urgent need for restoring insulin secretion function in diabetes patients, demonstrating the company's strategic commitment to the diabetes treatment landscape.
Biomea Fusion Unveils Clinical Results of Icovamenib, Advancing Diabetes Treatment
- Clinical Results Announcement: Biomea Fusion presented clinical findings on icovamenib at WCIRDC 2025, highlighting its potential efficacy in diabetes patients, which could position it as a new treatment option to meet the urgent market demand for innovative therapies.
- Key Opinion Leader Interview: Renowned expert Dr. Ralph DeFronzo discussed the mechanistic rationale for menin inhibition and the prospects of combining icovamenib with GLP-1 therapies, showcasing the drug's potential to improve glycemic control and insulin secretion, which may transform the diabetes treatment landscape.
- Market Demand Analysis: With approximately 38 million people in the U.S. living with diabetes and one in four healthcare dollars spent on diabetes care, the market potential for icovamenib is substantial, addressing a significant unmet medical need.
- Future Development Direction: Biomea Fusion emphasized the acceleration of icovamenib's clinical studies to address the high risks and rapid progression of severe insulin-deficient diabetes patients, demonstrating the company's strategic commitment to advancing diabetes care.
Biomea Fusion Highlights Long-lasting Advantages of Menin Inhibitor for Type 2 Diabetes
Study Presentation: Biomea Fusion Inc. presented new data from its COVALENT-111 study on Icovamenib for type-2 diabetes at the WCIRDC in Los Angeles, highlighting its potential to improve glycemic control in patients with inadequate management.
Mechanism and Results: Icovamenib, an investigational Menin inhibitor, showed durable improvements in glycemic levels and C-peptide after treatment, with better outcomes linked to higher drug exposure, and was well tolerated with no serious adverse events reported.
Future Trials: The company plans to initiate Phase IIb and Phase II trials (COVALENT-211 and COVALENT-212) in severe insulin-deficient type-2 diabetes and in combination with GLP-1 therapy, respectively, expected to start in Q4 2025.
Stock Performance: Biomea Fusion's stock is currently trading at $1.36, reflecting a 15.11% increase, with a 12-month trading range between $0.87 and $6.57.
Biomea Fusion Presents COVALENT-111 Study Results, New Breakthrough in Diabetes Treatment
- Study Results Presentation: Biomea Fusion presented COVALENT-111 study results at the WCIRDC in Los Angeles, demonstrating that icovamenib achieved durable improvements in HbA1c and C-peptide in patients with severe insulin-deficient type 2 diabetes, indicating its potential in diabetes treatment.
- Significant Clinical Effects: The study results showed a notable correlation between icovamenib use and HbA1c reduction, with treatment effects persisting nine months post last dose, suggesting its long-term efficacy.
- Good Safety Profile: In clinical trials, icovamenib was well-tolerated with no discontinuations due to adverse events, indicating a high safety profile that could enhance market acceptance among patients.
- Future Development Potential: As the first non-chronic therapy for type 2 diabetes, icovamenib could represent a significant innovation in diabetes treatment if it successfully completes ongoing clinical studies, addressing the growing global demand for diabetes management solutions.
Biotech Stocks Rise After Hours: Clene Jumps Ahead of ALS Update; Werewolf, Biomea, and Dyne Also Gain
Clene Inc. Gains: Clene Inc. shares rose 8.53% in after-hours trading after announcing an upcoming investor call regarding its CNM-Au8 program for ALS, despite a regular session decline.
Werewolf Therapeutics Update: Werewolf Therapeutics saw a 6.12% increase after hours, likely influenced by investor reactions to its recent presentation at a cancer immunotherapy conference, despite no new news.
Biomea Fusion Presentation: Biomea Fusion's stock climbed 7.31% after hours following its announcement of an upcoming presentation on icovamenib data at a major diabetes and cardiovascular disease congress.
General Market Trends: Other biotech companies like Denali Therapeutics, TScan Therapeutics, and Nyxoah also experienced after-hours gains, reflecting ongoing investor interest and positioning ahead of regulatory milestones and presentations.
